We investigate how abnormalities in the DNA of cells contribute to cancer and impact on patient responses to therapy. This provides fundamental insights into disease mechanisms with implications for the development of improved therapies.
There are currently four complementary research focuses in my laboratory:
- The genomics of drug sensitivity. High-throughput drug screens in human cancer cell cultures to identify genetic features of cancer cells that are predictive of drug sensitivity.
- Mapping synthetic-lethal dependencies in cancer cells. Genome-wide CRISPR-Cas9 synthetic-lethal screens in cancer cell lines to identify potential new oncology drug targets.
- A new generation of organoid cancer models. Methods for the derivation and characterisation of a new set of cancer organoid in vitro cell culture models.
- Precision organoid models to study cancer gene function. Genome-editing to introduce specific genetic alterations into healthy and cancer organoids to study their function.
To find out more indepth information please click on the read more button.